XML 85 R27.htm IDEA: XBRL DOCUMENT v3.25.3
Commitments and Contingencies (Details) - USD ($)
 6 Months Ended
Oct. 09, 2024
Mar. 10, 2021
Jun. 30, 2025
May 09, 2025
Commitments and Contingencies [Abstract]        
License consideration paid   $ 250,000    
Milestone payments due, description     (i) $750,000 payable following the end of a Phase II meeting with the FDA, with the amount to be reduced to $375,000 if toxicology studies must be repeated; (ii) $2 million following the earlier of FDA marketing authorization of Quilience or Nolazol; (iii) 1% of any upfront and milestone payments, if any, from any sublicensees and (iv) $3 million as a one-time payment upon the Company’s product candidate reaching $250 million in cumulative sales.  
Unpaid interest $ 110,179      
Interest rate, percentage 5.00%     5.00%